



ASX Announcement

21 January 2020

Creso exceeds the milestone of 3 million anibidiol® doses sold in Europe

Highlights

- In a milestone achievement, Creso Pharma has sold over three million anibidiol® portion sachets since the product was launched in late 2017. This volume is estimated to have benefitted over 100,000 dogs.
- Creso Pharma produces and markets anibidiol® in collaboration with Virbac S.A. (EPA:VIRP) in more than 10 countries.
- In addition, together with Virbac Switzerland, Creso Pharma has just launched the new product “anibidiol Oil 500” as a lifecycle management enhancement for the anibidiol® range.
- Two additional hemp-derived products aimed at improving the wellbeing of pets and pet owners will be launched by Creso Pharma in 2020.

Creso Pharma Limited (ASX:CPH, FRA:1X8) ('Creso Pharma' or 'the Company') is pleased to announce that over 100,000 dogs are estimated to have benefited from the Company's anibidiol® range of hemp oil complementary feed products.

This milestone corresponds to over 3 million portion sachets of anibidiol® granules used as complementary feed to help mitigate stress and improve wellbeing in dogs.

Creso Pharma developed anibidiol® and patented its granulated delivery system. It is produced in Switzerland and is commercialised in collaboration with Virbac S.A. (EPA:VIRP) in more than 10 countries in Europe. Its global sales grew approximately 700% in 2019.

anibidiol® Regular and anibidiol® Plus are commercialised for small, medium-sized and large pets to support the reduction of stress and aid in the functioning of the animals' nervous systems. Pet owners report anibidiol® has also contributed to the management of pain and improved the vitality of their pets after one week of use in addition to normal feed.



Image 1: anibidiol® 2.5 and anibidiol® 8



Images 3 and 4: anibidiol® regular

Creso Pharma has successfully developed 3 additional hemp-derived products to improve the wellbeing of pets, which are slated for launch during 2020.

Together with Virbac Switzerland, the Company recently launched its new anibidiol® Oil 500 product as a lifecycle management enhancement for the anibidiol® range, responding to strong demand from veterinaries and pet owners.

Initially the product will be marketed in Switzerland, with other national markets being added throughout 2020.



Dr Miri Halperin Wernli, Creso Pharma's CEO and co-founder said: "We are proud to see anibidiol® achieve this milestone, proving that pets and pet owners have an increasing appreciation of its benefits. This achievement is paving the way for launches into additional countries on other continents such as North and Latin America, where we observe a growing need for natural complementary feed to help mitigate stress and improve the wellbeing of pets. Creso Pharma hopes to continue leveraging the rising global trend of the 'humanisation' of pets, in which people treat their pets as best friends or family members."

Authority and Contact Details

This announcement has been authorised for release by Dr Miri Halperin Wernli, CEO and Managing Director of Creso Pharma Limited.

Ends

For further information, please contact:

Investor Enquiries

EverBlu Capital
E: info@everblucapital.com
P: +61 2 8249 0000

Media Enquiries

Julia Maguire | The Capital Network
E: julia@thecapitalnetwork.com.au
P: +61 419 815 386



About Creso Pharma

Creso Pharma Limited (ASX:CPH) brings the best of cannabis to better the lives of people and animals. It brings pharmaceutical expertise and methodological rigor to the cannabis world and strives for the highest quality in its products. It develops cannabis and hemp derived therapeutic, nutraceutical, and life style products with wide patient and consumer reach for human and animal health. Creso Pharma uses GMP (Good Manufacturing Practice) development and manufacturing standards for its products as a reference of quality excellence with initial product registrations in Switzerland. It has worldwide rights for a number of unique and proprietary innovative delivery technologies which enhance the bioavailability and absorption of cannabinoids. To learn more please visit: www.cresopharma.com

About Virbac

<https://corporate.virbac.com/home-en.html>

<https://www.virbac.ch/de/>

Virbac is an independent pharmaceutical laboratory dedicated to animal health, since its beginning. Currently the world's 7th largest animal health company with presence in more than 100 countries with more than 4,800 employees and sales subsidiaries in 33 countries. Virbac offers a comprehensive and practical range of products and services covering the majority of species and pathologies.

Forward Looking statements

This announcement contains forward-looking statements with respect to Creso and its respective operations, strategy, investments, financial performance and condition. These statements generally can be identified by use of forward-looking words such as "may", "will", "expect", "estimate", "anticipate", "intends", "believe" or "continue" or the negative thereof or similar variations.

The actual results and performance of Creso could differ materially from those expressed or implied by such statements. Such statements are qualified in their entirety by the inherent risks and uncertainties surrounding future expectations. Some important factors that could cause actual results to differ materially from expectations include, among other things, general economic and market factors, competition and government regulation.

The cautionary statements qualify all forward-looking statements attributable to Creso and persons acting on its behalf. Unless otherwise stated, all forward-looking statements speak only as of the date of this announcement and Creso has no obligation to up-date such statements, except to the extent required by applicable laws.